InterCure

InterCure Equity

The The Equity of InterCure (INCR.TA) as of Oct 9, 2026 is 501.31 M ILS. In the previous year, The Equity was 448.03 M ILS — a change of 11.89% (higher).

Equity

501.31 MILS

YoY

11.89%

Last updated:

In 2022, InterCure's equity was 501.31 M ILS, a 11.89% increase from the 448.03 M ILS equity in the previous year.

The InterCure Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2014
634,000.00 ILS
Jan 1, 2016
21.43 M ILS
Jan 1, 2017
21.72 M ILS
Jan 1, 2018
19.66 M ILS
Jan 1, 2019
255.97 M ILS
Jan 1, 2020
274.51 M ILS
Jan 1, 2021
448.03 M ILS
Jan 1, 2022
501.31 M ILS
The InterCure Equity history
YEAREquityYoY
501.31 MILS+11.89%
448.03 MILS+63.21%
274.51 MILS+7.24%
255.97 MILS+1,201.86%
19.66 MILS-9.47%
21.72 MILS+1.35%
21.43 MILS+3,279.76%
634,000.00ILS—
Access this data via the Eulerpool API

InterCure Stock analysis

What does InterCure do? InterCure Ltd. is a global company in the medical technology industry that focuses on the development, production, and distribution of innovative solutions for the diagnosis and treatment of chronic diseases. The company was founded in Israel in 2000 and is headquartered in Lod. InterCure is one of the most popular companies on Eulerpool.

Equity Details

Analyzing InterCure's Equity

InterCure's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding InterCure's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating InterCure's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

InterCure's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in InterCure’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about InterCure stock

The Equity of InterCure is 501.31 M ILS in 2022.

The Equity of InterCure changed from 448.03 M ILS to 501.31 M ILS, representing a 11.89% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity InterCure since 2006 – with annual values, charts, and detailed analysis.

The Equity's ILS is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's InterCure historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — InterCure

All Key Metrics — InterCure